SCHEMBL13316059

SCHEMBL13316059

CN1CCC(=O)c2cc(CC(C)(C)C)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.36
CTSD P07339 1/20 0.34
BACE1 P56817 1/20 0.34
SRD5A1 P18405 2/20 0.34
PARK7 Q99497 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
ESR1 P03372 1/20 0.33
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRB2 P47870 1/20 0.31
GABRA6 Q16445 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337453 0.84 ESR1 (0.33) HSD11B1CTSDBACE1MEN1ALDH1A1
SCHEMBL3161782 0.83 SRD5A1 (0.48) SRD5A1MEN1ALDH1A1GAAMAPT
SCHEMBL14706653 0.82 SRD5A1 (0.35) SRD5A1MEN1ALDH1A1GAAMAPT
SCHEMBL5731072 0.81 LMNA (0.40) SRD5A1MEN1ALDH1A1GAAMAPT
SCHEMBL13233322 0.78 PDE10A (0.43) CTSDBACE1MEN1ALDH1A1GAA
SCHEMBL23397539 0.73 PBRM1 (0.49) ESR1
SCHEMBL13539267 0.73 CASP3 (0.49) SRD5A1MEN1ALDH1A1GAAMAPT
SCHEMBL9127579 0.73 SRD5A1 (0.35) SRD5A1MEN1ALDH1A1GAAMAPT
SCHEMBL69760 0.73 OPRK1 (0.48) SRD5A1ALDH1A1GAAKMT2AGABRA1
SCHEMBL13316061 0.73 SRD5A1 (0.46) SRD5A1MEN1ALDH1A1KMT2AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100145056-A1 ACETYL 2-HYDROXY-1,3-DIAMINOALKANES JOHN VARGHESE 2010-06-10 US disclosed
US-7645780-B2 Acetyl 2-hydroxy-1, 3-diaminoalkanes ELAN PHARMACEUTICALS, INC. (US) 2010-01-12 US disclosed
US-7544717-B2 2-amino- and 2-thio- substituted 1,3-diaminopropanes ELAN PHARMACEUTICALS, INC. (US) 2009-06-09 US disclosed
US-20070293483-A1 Acetyl 2-hydroxy-1, 3-diaminoalkanes ELAN PHARMACEUTICALS, INC. 2007-12-20 US disclosed
US-7244725-B2 Acetyl 2-hydroxy-1, 3-diaminoalkanes ELAN PHARMACEUTICALS, INC. (US) 2007-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145056-A1 ACETYL 2-HYDROXY-1,3-DIAMINOALKANES BACE1, BACE2, APP HSD11B1 576/4885CTSD 185/4885BACE1 1/4885
US-20070293483-A1 Acetyl 2-hydroxy-1, 3-diaminoalkanes BACE1, BACE2, APP HSD11B1 576/4885CTSD 185/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.